The phosphoinositide 3-kinase (PI3K) signalling cascade occupies a central role in the regulation of cell growth, survival and metabolism, and its dysregulation represents one of the most frequent ...

Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC). Impact of metastases directed radiation therapy on CDK4/6 inhibitors ...

Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for ...

Combined analysis of tumor budding and tumor microenvironment in patients with stage III colorectal cancer.

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib ...

Low-dose aspirin during adjuvant chemotherapy did not significantly reduce risk for recurrence among unselected patients with ...

Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer ...